Women with breast cancer taking chemotherapy: depression symptoms and treatment adherence

Bianca Fresche de Souza, Jéssica Andrade de Moraes, Aline Inocenti, Manoel Antônio dos Santos, Ana Elisa Bauer de Camargo Silva, Adriana Inocenti Miasso, Bianca Fresche de Souza, Jéssica Andrade de Moraes, Aline Inocenti, Manoel Antônio dos Santos, Ana Elisa Bauer de Camargo Silva, Adriana Inocenti Miasso

Abstract

Objective: To verify depressive symptoms and adherence to chemotherapy among women with breast cancer who are served by the Pharmacy of the Chemotherapy Center of a university hospital.

Method: Cross-sectional study with quantitative approach conducted with 112 women receiving chemotherapy. Structured interviews guided by a script addressing socio-demographic, clinical and therapeutic information, the Morisky Test, and the Beck Depression Inventory were used to collect data.

Results: 12.50% and 1.78% of the patients experienced "moderate" and "severe" depression, respectively, while 10.59% did not use antidepressant medication. A statistically significant association was found between levels of depression and the use of antidepressants. Lack of adherence was identified in 46.43% of the participants.

Conclusion: These findings show the need to regularly screen for depressive symptoms and for adherence to chemotherapy treatment among women with breast cancer, in order to provide early detection and appropriate treatment centered on patients, and to improve their quality of life.

Figures

Figure 1. - Distribution of the study's…
Figure 1. - Distribution of the study's participants according to the intensity of depressive symptoms and use of anti-depressive medication
Figure 2. - Distribution of the study's…
Figure 2. - Distribution of the study's participants according to the classification of symptoms and adherence to chemotherapy treatment

References

    1. Ministério da Saúde(BR) Estimativa 2012: incidência de câncer no Brasil. Instituto Nacional de Câncer; Rio de Janeiro: INCA; 2011.
    1. Fann JR, Thomas-Rich AM, Katon WJ, Cowley D, Pepping M, McGregor BA, et al. Major depression after breast cancer: a review of epidemiology and treatment. Gen Hosp Psychiatry. 2008;30(2):112–126.
    1. Torres MA, Pace TW, Liu T, Felger JC, Mister D, Doho GH, et al. Predictors of depression in breast cancer patients treated with radiation: role of prior chemotherapy and nuclear factor kappa B. Cancer. 2013;119(11):1951–1959.
    1. Zainal NZ, Nik-Jaafar NR, Baharudin A, Sabki ZA, Ng CG. Prevalence of depression in breast cancer survivors: a systematic review of observational studies. Asian Pacific J Cancer Prev. 2013;14(4):2649–2656.
    1. Fanger PC, Azevedo RCS, Mauro MLF, Lima DD, Gaspar KC, Silva VF, et al. Depressão e comportamento suicida em pacientes oncológicos hospitalizados: prevalência e fatores associados. Rev Assoc Med Bras. 2010;56(2):173–178.
    1. Meneses K, McNees P, Azuero A, Jukkala A. Evaluation of the Fertility and Cancer Project (FCP) among young breast cancer survivors. Psychooncology. 2010;19(10):1112–1115.
    1. Reyes-Gibby CC, Anderson KO, Morrow PK, Shete S, Hassan S. Depressive symptoms and health-related quality of life in breast cancer survivors. J Womens Health (Larchmt) 2012;21(3):311–318.
    1. Bottino SMB, Fraguas R, Gattaz WF. Depressão e câncer. Rev Psiquiatr Clín. 2009;36(3):109–115.
    1. Kimmick G, Anderson R, Camacho F, Bhosle M, Hwang W, Balkrishnan R. Adjuvant hormonal therapy use among insured, low-income women with breast cancer. J Clin Oncol. 2009;27(21):3445–3451.
    1. Morisky DE, Green LW, Levine DM. Concurrent and predictive validity of a self-reported measure of medication adherence. Med Care. 1986;24(1):67–74.
    1. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatr. 1961;4:53–63.
    1. Hack TF, Pickles T, Ruether JD, Weir L, Bultz BD, Mackey J, et al. Predictors of distress and quality of life in patients undergoing cancer therapy: impact of treatment type and decisional role. Psychooncology. 2010;19(6):606–616.
    1. Silva PO, Gorini MIPC. Validation of defining characteristics for the nursing diagnosis of fatigue in oncological patients. Rev. Latino-Am. Enfermagem. 2012;20(3):504–510.
    1. Dodd MJ, Cho MH, Cooper BA, Miaskowski C. The effect of symptom clusters on functional status and quality of life in women with breast cancer. Eur J Oncol Nurs. 2010;14(2):101–110.
    1. Hermelink K, Kuchenhoff H, Untch M, Bauerfeind I, Lux MP, Buhner M, et al. Two different sides of 'chemobrain': determinants and nondeterminants of selfperceived cognitive dysfunction in a prospective, randomized, multicenter study. Psychooncology. 2010;19(12):1321–1328.
    1. Bauer M, Whybrow PC, Angst J, Versiani M, Möller HJ. Diretrizes da World Federation of Societies of Biological Psychiatry (WFSBP) para tratamento biológico de transtornos depressivos unipolares, 1ª parte: tratamento agudo e de continuação do transtorno depressivo maior. Rev Psiquiatr Clín. 2009;36(2):17–57.
    1. Lima AFBS, Fleck MPA. Quality of life, diagnosis, and treatment of patients with major depression: a prospective cohort study in primary care. Rev Bras Psiquiatr. 2011;33(3):245–251.
    1. Bio DS, Souza EL, Moreno RA. Remissão sintomática e qualidade de vida em pacientes com depressão maior tratados com antidepressivo: um estudo prospectivo. Aletheia. 2011;34:151–162.
    1. Ladd CO, Newport DJ, Ragan KA, Loughhead A, Stowe ZN. Venlafaxine in the treatment of depressive and vasomotor symptoms in women with perimenopausal depression. Depress Anxiety. 2005;22(2):94–97.
    1. Hershman D, Shao T, Kushi L, Buono D, Tsai W, Fehrenbacher L, et al. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011;126(2):529–537.
    1. Ma AM, Barone J, Wallis AE, Wu NJ, Garcia LB, Estabrook A, et al. Noncompliance with adjuvant radiation, chemotherapy, or hormonal therapy in breast cancer patients. Am J Surg. 2008;196(4):500–504.
    1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15 year survival: an overview of the randomised trials. Lancet. 2005;365:1687–1717.
    1. Ashraf M, Biswas J, Majumdar S, Nayak S, Alam N, Mukherjee KK, et al. Tamoxifen use in Indian women- adverse effects revisited. Asian Pac L Cancer Prev. 2009;10(4):609–612.
    1. Hershman DL, Kushi LH, Shao T, Buono D, Kershenbaum A, Tsai WY, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8.769 early-stage breast cancer patients. J Clin Oncol. 2010;28(27):4120–4128.
    1. Lash TL, Cronin-Fenton D, Ahern TP, Rosenberg CL, Lunetta KL, Silliman RA, et al. Breast cancer recurrence risk related to concurrent use of SSRI antidepressants and tamoxifen. Acta Oncol. 2010;49(3):305–312.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj